Investments in progress and portfolio companies

Learn about the companies developing tomorrow’s diagnostics, therapeutics and healthcare

Investments in progress​

Learn more about our ongoing investments. We have made our analysis, negotiated the terms and made our decision. We have compiled the information and documents for you to make your decision.

Everdrone AB

Everdrone offers a service where autonomous drones deliver defibrillators to cardiac arrest scenes, often minutes before an ambulance arrives. With proprietary tech and emergency system integration, Everdrone makes a difference when seconds count.

Read more

Investments in progress​

We are currently investing in one or more companies that passed our rigorous selection process. Please login or create an account to learn more and co-invest with us.

Our portfolio companies

Our portfolio companies are currently developing diagnostics for early detection of cancer via blood sample, saving lives in emergency care and surgery through software innovations, developing personalised treatments of severe diseases, and much more.

Synartro

Synartro is developing a unique treatment for knee osteoarthritis by combining two well-tried drugs, which will offer an effective and safe alternative to today’s treatments.

Read more

Neogap Therapeutics

NEOGAP Therapeutics develops a new type of personalised therapy for the treatment of cancer. The company uses proprietary machine learning algorithms and patented technology to tailor the treatment for each patient and its specific tumour cells.

Read more

Pharmnovo

PharmNovo is a pharmaceutical company at the clinical stage of developing a unique type of treatment for nerve pain (neuropathic pain), a condition currently lacking effective and safe treatment. The company is currently finalising its clinical phase I study and is advancing its preparations for a phase II study.

Read more

Capitainer

Capitainer develops and sells intelligent solutions for self-sampling blood, plasma, and urine. The products enable easy home sampling with market-leading precision, delivering value across the entire care chain.

Read more

Exits

Former portfolio companies that have reached new heights through acquisition or listing, and continue to thrive under new ownership. These companies continue to make a lasting impact in their respective industries.

Lipigon Pharmaceuticals

Lipigon develops orphan drugs for illnesses due to disorders in how the body handles fat. The company’s major program, Lipsense, focuses on the illness, HoFH, where there is, today, no sufficient treatment.

Read more